jte 522 has been researched along with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone in 1 studies
| Studies (jte 522) | Trials (jte 522) | Recent Studies (post-2010) (jte 522) | Studies (benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone) | Trials (benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone) | Recent Studies (post-2010) (benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone) |
|---|---|---|---|---|---|
| 61 | 1 | 7 | 1,897 | 0 | 411 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, DD; Li, HL; Li, XH; Lü, JH; Ren, XD; Wang, CC; Zhang, HW | 1 |
1 other study(ies) available for jte 522 and benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
| Article | Year |
|---|---|
JTE-522-induced apoptosis in human gastric adenocarcinoma [correction of adenocarcinoma] cell line AGS cells by caspase activation accompanying cytochrome C release, membrane translocation of Bax and loss of mitochondrial membrane potential.
Topics: Adenocarcinoma; Amino Acid Chloromethyl Ketones; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; bcl-2-Associated X Protein; Benzenesulfonates; Caspase Inhibitors; Caspases; Cyclooxygenase Inhibitors; Cysteine Proteinase Inhibitors; Cytochrome c Group; Enzyme Activation; Humans; In Situ Nick-End Labeling; Membrane Potentials; Mitochondria; Oxazoles; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms; Tumor Cells, Cultured | 2002 |